CTLA4 and neoplasm: Notably, the percentage of splenic Tregs CTLA-4+ and Tim-3+ CD4+ T cells were significantly decreased after combination therapy compared with those in the tumor-bearing control group (Figure 4C and Figure S7B,C), indicating that the suppressive CD4+ T subsets and exhausted CD4+ T cells were significantly reduced after combination therapy.